Evidence map›Paper›PMID 39920292›Full record

ReviewDie Ophthalmologie2025

[Treatment of central serous chorioretinopathy in comparison-Micropulse laser versus photodynamic therapy].

Vasilena Sitnilska, Ulrike Brocks, Jan Tode, Georg Spital, Lebriz Altay

Abstract readComparative StudyReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Die Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vasilena SitnilskaZentrum für Augenheilkunde, Medizinische Fakultät und Uniklinik Köln, Universität zu Köln, Köln, Deutschland. vasilena.sitnilska@gmail.com.ORCID http://orcid.org/0000-0002-0886-4263
Ulrike BrocksKlinik und Poliklinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
Jan TodeUniversitätsklinik für Augenheilkunde Hannover, Medizinische Hochschule Hannover, Hannover, Deutschland.
Georg SpitalAugenzentrum am St. Franziskus-Hospital, Münster, Deutschland.
Lebriz AltayZentrum für Augenheilkunde, Medizinische Fakultät und Uniklinik Köln, Universität zu Köln, Köln, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic management of central serous chorioretinopathy (CSC) remains challenging. Although CSC shows a high rate of self-resorption, frequent recurrences or chronification of the disease can result in irreversible loss of vision. Low-dose photodynamic therapy (half-dose or half-fluence PDT) represents the current standard of care for CSC, although regenerative laser procedures may also offer a safe and effective alternative for the treatment of CSC.

Indexed as

Central Serous ChorioretinopathyLaser TherapyPhotochemotherapyHumansPhotosensitizing AgentsTreatment OutcomePhotosensitizing AgentsLaser treatmentMicropulse laserPhotomicrodisruptive therapyPhotothermic therapySelective retinal treatment

Identifiers

PMID39920292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.